ALX Oncology Holdings Inc
(NAS:ALXO)
$
1.62
-0.07 (-4.14%)
Market Cap: 85.44 Mil
Enterprise Value: -49.60 Mil
PE Ratio: 0
PB Ratio: 0.63
GF Score: 27/100 ALX Oncology Holdings Inc at H C Wainwright Global Life Sciences Conference (Virtual) - Pre-Recorded Fireside Chat Transcript
Mar 09, 2021 / 12:00PM GMT
Release Date Price:
$73.54
(+5.68%)
Swayampakula Ramakanth
H.C. Wainwright & Co, LLC, Research Division - MD of Equity Research & Senior Healthcare Analyst
Good day, and thanks for joining us to have a conversation with Jaume Pons, CEO; and Sophia Randolph, CMO of ALX Oncology. ALX Oncology is developing novel antibodies targeting the CD47-SIRPalpha axis. This -- their lead asset, ALX148, is being tested in the clinic as a therapy for treating solid tumors, a first for anti-CD47 therapies.
To discuss the clinical development to date, the expected progress in 2021 and beyond, I welcome Jaume and Sophia to this fireside chat. Jaume and Sophia, glad to see you both and accepting our invitation to talk to our audience today.
Jaume Pons
ALX Oncology Holdings Inc. - President, CEO & Director
Thank you.
Sophia Randolph
ALX Oncology Holdings Inc. - Chief Medical Officer
Thank you.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot